Atossa Genetics

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

AT-301 Intended to Prevent COVID-19 and Treat Early Cases Via Nasal Delivery AT-301 Intended to Prevent COVID-19 and Treat Early Cases Via Nasal Delivery

Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study

Atossa Therapeutics (NASDAQ: ATOS) shares are trading higher on Wednesday. The company announced "successful" in vitro testing results of AT-H201, which is Atossa's proprietary COVID-19 drug candidate.

Why Atossa Therapeutics Stock Is Trading Higher Today

Results Support Development of AT-H201 for COVID-19 Patients Results Support Development of AT-H201 for COVID-19 Patients

Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

SEATTLE, May  13, 2020  (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced financial results for the first quarter ended March 31, 2020, and provided an update on recent company developments.

Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs

SEATTLE, May  07, 2020  (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:  ATOS  ), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced positive interim results from its Phase 2 study of oral Endoxifen to treat breast cancer in the window of opportunity between diagnosis of breast cancer and surgery. A statistically significant (p = 0.031) reduction of about 74% in tumor cell proliferation was achieved over the 22 days of dosing. Proliferation was measured by Ki-67, a recognized standard measurement of breast cancer cell proliferation.

Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment

Atossa Therapeutics Inc. (NASDAQ: ATOS) is the newest company to join the fight against COVID-19.

Atossa Therapeutics Is Thursday’s Big Coronavirus Winner

Combination of two drugs previously approved by the FDA for other diseases to be developed to reduce patient time on a ventilator Combination of two drugs previously approved by the FDA for other diseases to be developed to reduce patient time on a ventilator

Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program

Company’s Clinical Development Has Not Been Impacted by COVID-19 Company’s Clinical Development Has Not Been Impacted by COVID-19

Atossa Therapeutics Announces Upcoming Meeting with FDA

Speculative Spotlight: Atossa Therapeutics Offers An Enticing Risk-Reward

SEATTLE, Jan.  22, 2020  (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders:

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020

SEATTLE, Dec.  19, 2019  (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:  ATOS  ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it has contracted with Stockholm South General Hospital in Sweden to conduct a Phase 2 study of Atossa’s proprietary oral Endoxifen to reduce mammographic breast density (MBD) in women. The study is being led by principal investigator Per Hall, M.D., Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. MBD is an emerging public health issue, as studies conducted by others have shown that MBD increases the risk of developing breast cancer and that reducing MBD can reduce the incidence of breast cancer.

Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women

SEATTLE, Oct.  23, 2019  (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:  ATOS  ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO and General Counsel of Atossa Genetics will be a featured presenter at the 5th Annual Dawson James Small Cap Growth Conference on October 29, 2019 at 11:20 AM Eastern Time. The conference is being held at the Wyndham Grand Hotel in Jupiter, Florida.

Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

Susan Love, M.D., inventor of the technology, will advise Atossa on the study Susan Love, M.D., inventor of the technology, will advise Atossa on the study

Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology

All Objectives Successfully Met – Phase 2 Study to Start Q4 2019 All Objectives Successfully Met – Phase 2 Study to Start Q4 2019

Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen

SEATTLE, Sept.  06, 2019  (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:  ATOS  ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO and General Counsel of Atossa Genetics will be a featured presenter at the 21st Annual Rodman and Renshaw Global Investor Conference on Tuesday September 10, 2019 at 4:15 PM Eastern Time. The conference is being held at the Lotte New York Palace Hotel in New York City.

Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

Preliminary Results Expected within 30 Days Preliminary Results Expected within 30 Days

Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet

The recent price spike in Atossa Genetics' shares from $1.51 to $7.39 on 3/14/19 was followed by a sharp decline to $3.31 on 3/15/19. The stock closed $3.97 on 3/26/19.

Atossa's 50% Retrace May Be Set Up For Next Leg Higher

Atossa Genetics Inc. had a wild week last week after announcing that its proprietary oral Endoxifen was granted "Expanded Access" by the FDA for Post-Mastectomy Treatment for a U.S. Breast Cancer Patient.

Atossa Genetics: Expect More Near-Term Positive Catalysts After Continued FDA Approval For One Patient

News for Atossa Genetics Stock (ATOS)